No human data · Grade D
Follistatin
Follistatin (FST-344)
Evidence
No Human Data
Route
Subcutaneous injection
Frequency
Not applicable as a repeatable dose; the studied gene therapy was a one-time intramuscular gene-transfer procedure, not an ongoing injection schedule.
Category
Metabolic & Body Composition
TL;DR
Follistatin is a protein your body already makes that blocks "muscle-limiting" signals called myostatin and activin. When those signals are turned down, animals build a lot more muscle, which is why follistatin has drawn so much attention. But the reality is that there is no approved follistatin medicine, and the only human studies are a few very small gene-therapy experiments in rare muscle diseases, plus a newer combined gene-therapy program that started in late 2025. Those studies were too small and uncontrolled to prove that follistatin works or to know whether it is safe over time. Injectable follistatin sold online is not the same thing as those studied gene therapies, is unregulated, and carries real unknown risks. For now, follistatin is best understood as early-stage science — one to follow rather than to try, and a conversation to have with a qualified clinician before anything else.
Part 01 · How it works
Mechanism.
Follistatin (FST-344, also written FS344) is a naturally occurring secreted glycoprotein that binds and neutralizes members of the TGF-beta superfamily, most notably myostatin and activin, which normally act as brakes on skeletal muscle growth. It is not a small synthetic research peptide but a large endogenous protein, and there is no FDA-approved follistatin therapeutic of any kind. Nearly all human work to date has used gene therapy, in which an adeno-associated virus (AAV) vector is engineered to make the FST344 isoform inside muscle, rather than the injectable follistatin products marketed in the wellness space. Small early-phase, single-arm gene-therapy trials in Becker muscular dystrophy and sporadic inclusion body myositis were conducted at Nationwide Children's Hospital, and a combined Klotho-plus-follistatin gene-therapy program entered the clinic in late 2025. Because human evidence is limited to a handful of uncontrolled studies, follistatin should be understood as an experimental, preclinical-to-early-stage molecule, not an established treatment. The FST344 designation refers to a specific alternatively spliced isoform chosen in those trials to reduce binding at off-target sites.
Think of myostatin and activin as the governor on a car engine, capping how much muscle the body will build. Follistatin works like a clamp placed over that governor: with the limiter held back, the engine is freed to run higher. The catch is that almost all of what we know about flooring this particular accelerator comes from animals and a few small human gene-therapy experiments, so the long-term behavior of the engine in people is still largely uncharted.
Mechanism · technical
Follistatin is a high-affinity binding protein for several TGF-beta superfamily ligands. By binding circulating and tissue myostatin (GDF-8) and activin A, it prevents those ligands from engaging the activin type II receptors (ActRIIA/ActRIIB) on muscle cell membranes. Because myostatin and activin signaling through these receptors normally drives the SMAD2/3 pathway to restrain muscle protein synthesis and promote protein breakdown, sequestering them removes a brake on muscle growth and shifts the balance toward hypertrophy and satellite-cell-mediated regeneration in animal models. The FST344 isoform was selected in the Nationwide Children's gene-therapy work as an alternatively spliced form intended to limit binding to off-target sites such as heparan sulfate on the cell surface. Animal data show follistatin can increase muscle mass beyond what myostatin loss alone produces, indicating it acts on additional ligands (such as activins and other GDFs), not myostatin exclusively.
Part 02 · Dosing & administration
How it's taken.
No validated doseNo independently validated human dosing exists for Follistatin. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
Dose
No validated dose
These figures describe published clinical-trial gene-therapy parameters only and are not a usage recommendation. The studied product was delivered intramuscularly under research conditions; the route field is set per the requested schema. Unapproved injectable follistatin products sold commercially are not the studied gene therapy and have no evidence-based dose. No safe self-administration protocol has been established.
Need help with reconstitution?
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Part 03 · Safety
Side effects, rare serious events, who shouldn't.
Reported side effects
The human safety profile is poorly characterized because exposure is limited to small, single-arm gene-therapy studies. In those trials of intramuscular AAV1-delivered FST344, investigators reported no serious adverse events attributed to the vector, but the cohorts were tiny (roughly six patients each), follow-up was limited, and no placebo-controlled safety data exist. Theoretical and mechanism-based concerns include immune responses to the viral vector or transgene product, local injection-site reactions, and the consequences of broadly inhibiting TGF-beta/activin signaling, which has roles in cardiac tissue, tendon and connective tissue integrity, reproductive endocrinology, and tumor surveillance. Injectable follistatin products sold outside the regulated drug supply carry additional unquantified risks of contamination, inaccurate dosing, and unknown long-term effects. None of this should be read as a safety endorsement; it reflects how little controlled human data exist.
Absolute · do not use
×
Pregnancy, breastfeeding, or active attempts to conceive, given unknown effects on the fetus and on activin/FSH-dependent reproductive signaling
×
Any active or prior malignancy or elevated cancer risk, because broadly suppressing TGF-beta/activin signaling could theoretically affect tumor surveillance
×
Known or suspected cardiac disease, since TGF-beta/activin pathways contribute to cardiac tissue homeostasis and systemic inhibition is unstudied in this setting
×
Use of unregulated, non-pharmaceutical injectable follistatin products from the gray market, due to unknown purity, dosing, and immune risk
×
Children and adolescents, who have no safety data and ongoing developmental TGF-beta signaling
×
Anyone unwilling or unable to be monitored by a qualified clinician, given the absence of established safety parameters
Interactions
Myostatin/activin pathway inhibitors (e.g., investigational ActRII antibodies, anti-myostatin antibodies such as bimagrumab or trevogrumab)
Overlapping mechanism could compound the effects and unknown risks of inhibiting TGF-beta/activin signaling; no combination data exist
Theoretical
GLP-1 receptor agonists used for weight loss (e.g., semaglutide, tirzepatide)
Reviews discuss myostatin/activin pathway modulation alongside incretin-driven weight loss to preserve lean mass, but this is an unstudied combination for follistatin and remains speculative
Theoretical
Anabolic-androgenic steroids or other muscle-building agents
Stacking with unapproved anabolic agents amplifies cardiovascular, hepatic, and other unmonitored risks with no supporting safety evidence
Theoretical
Immunosuppressants or vaccines (in the context of AAV gene therapy)
Immune status can affect viral-vector gene-therapy outcomes and vector-directed immune responses; relevant only to the investigational gene-therapy form
Moderate
Labs to monitor
Comprehensive metabolic panel (including liver and kidney function)
Baseline and as directed by a supervising clinician
General safety baseline for any investigational injectable; the activin/myostatin system intersects with metabolic and kidney pathways, and there is no follistatin-specific monitoring standard
Creatine kinase (CK)
Baseline and periodically if used under medical supervision
Reflects muscle turnover and injury; relevant when interventions target skeletal muscle, and useful as a nonspecific safety marker
High-sensitivity CRP / inflammatory markers
Baseline and if symptoms of inflammation arise
Helps flag immune or inflammatory responses, a theoretical concern with vector-delivered or unregulated protein products
Reproductive hormone panel (e.g., FSH) when clinically relevant
Baseline if reproductive effects are a concern, then per clinician
The activin-inhibin-follistatin system regulates FSH and reproductive function; systemic modulation could have endocrine effects, particularly in women
Part 04 · Research log
Every study we cite.
Each study with its published finding and a plain-language note on limitations or funding.
01
2014
0
Phase 1/2a follistatin (FS344) AAV1 gene-therapy trial in Becker muscular dystrophy
In an open-label proof-of-principle study, six Becker muscular dystrophy patients received bilateral intramuscular quadriceps injections of AAV1.CMV.FS344; four of six showed improvements on the 6-minute walk test (ranging about 29 to 125 meters) while two showed no change, and muscle biopsies showed reduced fibrosis and fiber hypertrophy, with no adverse effects reported.
Very small (n=6), open-label, single-arm with no placebo or randomization, so improvements cannot be reliably separated from natural variability, exercise, or expectation effects. Academic gene-therapy center study; findings are hypothesis-generating only.
PMID 25322757 ↗
02
2017
0
Follistatin (FS344) AAV1 gene-therapy trial in sporadic inclusion body myositis
In six patients with sporadic inclusion body myositis given intramuscular AAV1 follistatin to the quadriceps alongside an exercise regimen, annualized 6-minute walk distance was reported as +56.0 m/year in treated subjects versus -25.8 m/year in eight matched untreated subjects (p=0.01), with histology showing decreased fibrosis and improved regeneration.
Small, non-randomized, with a non-concurrent matched (not placebo) comparison group and a concurrent exercise program that confounds attribution to the vector. More advanced disease responded poorly. Single academic center; results are preliminary.
PMID 28279643 ↗
03
2007
0
Follistatin overexpression quadruples muscle mass in mice by targeting TGF-beta pathways
In a mouse genetic study, myostatin-null mice also carrying a follistatin transgene developed roughly four times the muscle mass of wild-type mice, demonstrating in animal models that follistatin increases muscle beyond myostatin loss alone and therefore acts on additional TGF-beta ligands.
Animal model only with no human relevance established; uses genetic overexpression rather than any administered drug, so it does not predict efficacy or safety of follistatin given to people.
PMID 17726519 ↗
04
2025
0
Review: myostatin inhibitors, including follistatin-based strategies, in sarcopenia
This 2025 review summarized that myostatin-targeted approaches, including indirect modulators such as follistatin-based strategies, were associated with increased muscle mass and improved muscle function in preclinical and early clinical studies, while noting that effective approved pharmacological treatments for sarcopenia remain limited.
Narrative review, not a meta-analysis; aggregates heterogeneous preclinical and early-phase data and shares the optimistic framing common to therapeutic-target reviews. No definitive efficacy conclusions for follistatin in humans.
PMID 41460393 ↗
05
2024
0
Review: the myostatin-activin-follistatin-inhibin system in weight loss and lean-mass preservation
This 2024 review described how, during negative energy balance, follistatins inhibit myostatin and activin activity to help preserve lean mass, and discussed activin/myostatin pathway inhibitors as candidates being studied to limit muscle loss while promoting fat loss, noting that well-designed studies are still needed.
Review article summarizing mechanism and an emerging drug pipeline rather than follistatin outcomes specifically; conclusions are exploratory and the cited pipeline agents are distinct molecules, not follistatin.
PMID 39481534 ↗
Part 05 · Cost & access
Where you can get it.
Regulatory status
Follistatin is not approved by the FDA for any indication. It is an endogenous glycoprotein, not an approved drug or a dietary supplement, and it has not been demonstrated safe or effective for any use in adequate, well-controlled human trials. Human exposure has occurred only within investigational gene-therapy clinical trials conducted under regulatory oversight. Follistatin is not a compounding-pharmacy-recognized active ingredient and appears on the FDA's list of bulk substances that should not be used in compounding. Injectable "follistatin" products marketed for muscle growth or anti-aging are unapproved and fall outside the legal regulated drug supply; their sale and use raise significant regulatory and safety concerns. This entry is educational and is not medical advice or an offer to sell any product.
The Peptide Column takes no affiliate commission from any source.
Part 06 · Your appointment
Questions to bring.
01
Given that no follistatin product is FDA-approved and human data come only from small uncontrolled gene-therapy trials, is there any legitimate medical role for it in my situation?
02
How would systemic, unregulated myostatin and activin inhibition affect my heart, tendons, and other tissues that also rely on TGF-beta signaling?
03
If I have a muscle, neuromuscular, or metabolic condition, what therapies with actual regulatory approval and controlled-trial evidence should we discuss instead?
04
What are the risks of injectable 'follistatin' products sold outside the regulated supply chain, including purity, dosing, and immune reactions?
References
Every citation, numbered.
Citation list. For our editorial read of each study — including bias flags and quality grades — see the Research log above.
- 01. Phase 1/2a follistatin (FS344) AAV1 gene-therapy trial in Becker muscular dystrophy · 2014 · PMID 25322757 ↗
- 02. Follistatin (FS344) AAV1 gene-therapy trial in sporadic inclusion body myositis · 2017 · PMID 28279643 ↗
- 03. Follistatin overexpression quadruples muscle mass in mice by targeting TGF-beta pathways · 2007 · PMID 17726519 ↗
- 04. Review: myostatin inhibitors, including follistatin-based strategies, in sarcopenia · 2025 · PMID 41460393 ↗
- 05. Review: the myostatin-activin-follistatin-inhibin system in weight loss and lean-mass preservation · 2024 · PMID 39481534 ↗